SHANGHAI (Reuters) -Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

How long does Ozempic stay in your system? What to expect after stopping, including clearance time, side effects, and factors that influence it.

Drug services provider Medtide (3880.HK) is looking to raise HK$514 million (410 million yuan or $65.48 million) in a listing ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss drug, may lower the risk of dementia in people with type 2 diabetes ...

Novo Nordisk NVO ended its collaboration agreement with telehealth company Hims & Hers Health HIMS to offer its blockbuster ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

Hims & Hers Health stock plunged after Novo Nordisk (NYSE: NVO) cut ties over concerns about its handling of Wegovy ...